On March 21, 2024, Loyal for Dogs (Loyal), a biotech company pioneering longevity drugs for dogs, announced the completion of a $45 million Series B funding round led by Bain Capital Ventures. Wilson Sonsini Goodrich & Rosati advised Loyal on patent matters related to the Series B and represents the company in patent strategy and prosecution matters.

The Series B brings total funding raised by Loyal to more than $125 million since its founding in 2019. The additional capital will support Loyal's continued development with expected product launch in early 2025, pending FDA approval.

The Wilson Sonsini team that advises Loyal on patent strategy and prosecution matters includes Ying Chen, Scott Burkette, Christina Hoong, and Mike Hostetler.

For more information, please see Loyal's news release. Additional coverage can be found on The Wall Street Journal and Veterinary Practice News.